Logo image of AARD

AARDVARK THERAPEUTICS INC (AARD) Stock Price, Quote, News and Overview

NASDAQ:AARD - Nasdaq - US0029421007 - Common Stock - Currency: USD

10.52  +0.22 (+2.14%)

AARD Quote, Performance and Key Statistics

AARDVARK THERAPEUTICS INC

NASDAQ:AARD (5/30/2025, 1:13:28 PM)

10.52

+0.22 (+2.14%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap228.28M
Shares21.70M
Float18.59M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO02-13 2025-02-13


AARD short term performance overview.The bars show the price performance of AARD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10

AARD long term performance overview.The bars show the price performance of AARD in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of AARD is 10.52 USD. In the past month the price decreased by -7.29%.

AARDVARK THERAPEUTICS INC / AARD Daily stock chart

AARD Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 53.46 697.14B
JNJ JOHNSON & JOHNSON 15.39 372.10B
NVO NOVO-NORDISK A/S-SPONS ADR 19.89 314.59B
NVS NOVARTIS AG-SPONSORED ADR 13.83 226.99B
AZN ASTRAZENECA PLC-SPONS ADR 16.51 225.27B
MRK MERCK & CO. INC. 9.91 193.85B
PFE PFIZER INC 7.32 133.52B
SNY SANOFI-ADR 11.2 119.92B
BMY BRISTOL-MYERS SQUIBB CO 6.55 97.87B
GSK GSK PLC-SPON ADR 9.25 83.15B
ZTS ZOETIS INC 28.12 75.36B
HLN HALEON PLC-ADR 23.12 51.02B

About AARD

Company Profile

Aardvark Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in San Diego, California and currently employs 22 full-time employees. The company went IPO on 2025-02-13. The firm targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. The company is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).

Company Info

AARDVARK THERAPEUTICS INC

4370 La Jolla Village Drive, Suite 1050

San Diego CALIFORNIA US

Employees: 22

AARD Company Website

Phone: 18582257696

AARDVARK THERAPEUTICS INC / AARD FAQ

What is the stock price of AARDVARK THERAPEUTICS INC today?

The current stock price of AARD is 10.52 USD. The price increased by 2.14% in the last trading session.


What is the ticker symbol for AARDVARK THERAPEUTICS INC stock?

The exchange symbol of AARDVARK THERAPEUTICS INC is AARD and it is listed on the Nasdaq exchange.


On which exchange is AARD stock listed?

AARD stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for AARDVARK THERAPEUTICS INC stock?

10 analysts have analysed AARD and the average price target is 32.13 USD. This implies a price increase of 205.42% is expected in the next year compared to the current price of 10.52. Check the AARDVARK THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is AARDVARK THERAPEUTICS INC worth?

AARDVARK THERAPEUTICS INC (AARD) has a market capitalization of 228.28M USD. This makes AARD a Micro Cap stock.


How many employees does AARDVARK THERAPEUTICS INC have?

AARDVARK THERAPEUTICS INC (AARD) currently has 22 employees.


What are the support and resistance levels for AARDVARK THERAPEUTICS INC (AARD) stock?

AARDVARK THERAPEUTICS INC (AARD) has a support level at 9.88 and a resistance level at 10.45. Check the full technical report for a detailed analysis of AARD support and resistance levels.


Should I buy AARDVARK THERAPEUTICS INC (AARD) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does AARDVARK THERAPEUTICS INC (AARD) stock pay dividends?

AARD does not pay a dividend.


What is the Price/Earnings (PE) ratio of AARDVARK THERAPEUTICS INC (AARD)?

AARDVARK THERAPEUTICS INC (AARD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.96).


What is the Short Interest ratio of AARDVARK THERAPEUTICS INC (AARD) stock?

The outstanding short interest for AARDVARK THERAPEUTICS INC (AARD) is 1.87% of its float. Check the ownership tab for more information on the AARD short interest.


AARD Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to AARD.


Chartmill TA Rating
Chartmill Setup Rating

AARD Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to AARD. While AARD has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AARD Financial Highlights

Over the last trailing twelve months AARD reported a non-GAAP Earnings per Share(EPS) of -0.96. The EPS decreased by -185.61% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -24.59%
ROE -25.55%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-330.29%
Sales Q2Q%N/A
EPS 1Y (TTM)-185.61%
Revenue 1Y (TTM)N/A

AARD Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to AARD. The Buy consensus is the average rating of analysts ratings from 10 analysts.


Ownership
Inst Owners24.9%
Ins Owners31.14%
Short Float %1.87%
Short Ratio2.87
Analysts
Analysts84
Price Target32.13 (205.42%)
EPS Next Y-173.33%
Revenue Next YearN/A